HC Wainwright Boosts Pyxis Oncology (NASDAQ:PYXS) Price Target to $7.00

Pyxis Oncology (NASDAQ:PYXS – Free Report) had its target price boosted by HC Wainwright from $4.00 to $7.00 in a report issued on Friday morning, Benzinga reports. They currently have a buy rating on the stock. Several other research firms also recently commented on PYXS. BTIG Research started coverage on Pyxis Oncology in a report […]

Related Keywords

Leerink Partnrs , Prelude Capital Management , Commonwealth Equity Services , Pyxis Oncology Company Profile , Pyxis Oncology Inc , Acadian Asset Management , Pyxis Oncology , Free Report , Capital Management , Asset Management , Investment Advisers , Equity Services , Get Free Report , Pyxis Oncology Daily ,